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Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC)
over the last decade, with the development of agents that block the vascular endothelial
growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway.The
incorporation of these agents into treatment algorithms has been the result of carefully
conducted clinical trials leading to Food and Drug Administration (FDA) approval and subse-
quent adoption as the current standard of care. These trials, however, were dominated by
patients with clear cell renal cell carcinoma (ccRCC), and little data are currently available
on the treatment of non-clear cell renal cell carcinoma (nccRCC). nccRCC encompasses
a biologically heterogeneous group of kidney tumors that portend very diverse prognoses
and responses to therapy. This review is a pathway based approach that highlights the
current systemic treatment strategies for metastatic nccRCC.
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INTRODUCTION
EPIDEMIOLOGY OF nccRCC
Kidney cancer is the eighth most common malignancy in the
United States. There are approximately 65,000 new cases and
13,000 deaths per year due to kidney cancer (1), making it the most
lethal of the common urologic malignancies. RCC is the predomi-
nant form of primary renal malignancies. RCC is actually a family
of tumors, each with distinct genetic landscapes resulting in a
heterogeneous group of disease processes. The neoplasms catego-
rized as RCC’s exhibit diverse growth patterns, metastatic poten-
tials, and responses to treatment (2). By far the most common
RCC is clear cell [clear cell renal cell carcinoma (ccRCC)], which
accounts for 75–80% of all primary kidney malignancies (3). The
next most prevalent histologies include papillary (10–15%), chro-
mophobe (5%), collecting duct/medullary carcinomas (1–2%),
translocation associated RCC (<1%), and unclassified (~5%).
SUBTYPES OF nccRCC
Papillary RCC’s are tumors characterized histologically by a pre-
dominantly papillary cellular architecture (4). These tumors arise
from the proximal convoluted tubule portion of the nephron (5).
Papillary tumors are further subdivided into type 1 and type 2
classifications. Sporadic type 1 papillary RCC’s typically present as
multifocal tumors, although they tend to exhibit slow growth rates
and low metastatic potential when compared to ccRCC (6). It has
been suggested that this malignancy may occur at a higher rate in
black patients (7). These tumors are closely linked to genetic alter-
ations in the met oncogene (c-Met), which encodes the receptor
for hepatic growth factor (HGF) (8). A germline mutation in c-Met
is the etiology for hereditary papillary renal carcinoma, a familial
syndrome that causes bilateral, multifocal papillary type 1 tumors
in massive quantities (sometimes greater than 1,000 tumors per
kidney) (9). Papillary type 1 malignancies can also arise in a spo-
radic fashion. These tumors are commonly associated with c-Met
gene amplification and, less often, mutations within the c-Met
gene.
In contrast, type 2 papillary RCC tends to have a more aggres-
sive clinical course leading to higher rates of metastasis and
decreased survival (10). The inherited form of the disease has
been associated with germline mutations in the fumarate hydratase
gene (FH) (11). This gene is intimately involved in the Krebs cycle
and when inactivated leads to an accumulation of fumarate and
stabilization of the HIF1-α complex (12). Patients with this con-
dition, also known as hereditary leiomyomatous RCC, present
with cutaneous and uterine leiomyomas as well as kidney can-
cer (13). The renal tumors should not be managed expectantly in
those with this condition as they tend to behave aggressively (14).
They are typically locally infiltrative into the surrounding normal
parenchyma and should be resected with a wide margin to prevent
local recurrence (15).
Chromophobe RCC accounts for 5% of all primary renal malig-
nancies. These tumors arise from the intercalated cells of the distal
nephron and appear histologically as solid sheets of cells with
eosinophilic cytoplasm (5). These tumors typically behave indo-
lently and rarely metastasize (16). Mutations in the folliculin gene
located on chromosome 17 lead to Birt Hogg Dubé disease, char-
acterized by cutaneous fibrofolliculomas, pneumothoraces, and
chromophobe RCC (17). Patients with this condition may also
present with oncocytomas and hybrid oncocytic renal masses.
One of the least common and highly aggressive forms of RCC
is the collecting duct subtype. These tumors account for roughly
1–2% of all primary renal tumors. They arise from the collecting
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duct epithelia and are histologically and genetically closely linked
to urothelial tumors of the upper tract (5). They are more likely
to present as advanced disease when compared to other renal
tumors (18). A variant of this tumor known as medullary car-
cinoma presents most commonly in patients with sickle cell trait
(19) and is associated with the loss of SMARCB1/INI1 expression
(20). Overall, collecting duct carcinomas metastasize early and
have a poor prognosis. Additionally, there are very few effective
systemic treatments available for this disease.
There are many chromosomal translocations causing disrup-
tion in the microphthalmia-associated transcription factor (MiT)
family of genes that have been implicated in a subtype of RCC
known as translocation associated RCCs (21). The three main
culprit genes are Transcription factor E3 (TFE3), Transcription
factor EB (TFEB), and MITF (14). These tumors have a propen-
sity to present at a young age and represent up to 45% of kidney
tumors in children (22). The recommended treatment of translo-
cation associated RCCs is immediate surgical resection along with
lymph node dissection, as they can often present with early nodal
metastasis.
Another rare subtype of RCC is unclassified RCC (~5%).
This family of tumors typically contains unfavorable histology
and result in poor clinical outcomes, although it is possible that
this is a consequence of these tumors presenting with advanced
clinicopathologic features compared to ccRCC (23).
GENETIC SIGNATURES IN RCC
Great strides in our understanding of the genomic landscape of
RCC have been made in the last decade. This last year marked the
completion of two large scale studies that comprehensively ana-
lyzed the somatic alterations responsible for ccRCC (24, 25). These
multiplatform genetic analyses of over 500 tumors characterized
the oncogenic signature of this disease. While this effort sheds
some light on driver genes of RCC, the study was limited to the
clear cell subtype. The altered pathways identified in these analyses
may not play the same role in the tumorigenesis of non-clear cell
renal cell carcinoma (nccRCC). For example, ccRCC is a disease
with a strong association with 3p loss, an alteration that is not
typically present in nccRCC. More recently, the Cancer Genome
Atlas (TCGA) sequenced 66 primary chromophobe RCC tumors,
revealing an overall simpler genomic landscape than that of its
clear cell counterpart (26). Interestingly, 23% of chromophobe
tumors contained at least one mutation in the mTOR signal-
ing pathway (mTOR, NRAS, TSC1/2), indicating that therapeutic
targeting of this pathway may be a worthwhile strategy (27).
CLINICAL OUTCOMES IN METASTATIC nccRCC
Data from the International Metastatic Renal Cell Carcinoma
Database Consortium (IMDC) show that the diversity of renal
tumors is not just limited to their biologic blueprints, but is
reflected in its behavior, which impacts clinical outcomes as well
(28). nccRCC patients had a significantly worse overall survival
than their clear cell counterparts (12.8 vs 22.3 months, respec-
tively) (Figure 1). The nccRCC patients were then subdivided into
specific histologies, revealing the best survival among patients with
chromophobe tumors, followed by papillary tumors, and then
unclassified.
FIGURE 1 | Kaplan–Meier estimates of overall survival in all patients
with clear cell histology vs non-clear cell histology.
TREATMENT OPTIONS
The systemic treatment of metastatic RCC has been largely dic-
tated by clinical trials in which clear cell histologies predominate
the study population. It would be inaccurate to extrapolate these
results to tumors of non-clear cell histology due to the diversity
of genomic landscape and molecular architecture from which they
arise (29). Due to the scarcity of level 1 data on these tumors, there
is no current consensus on appropriate first line treatment. The
National Comprehensive Cancer Network (NCCN) recommends
enrollment in a clinical trial as the preferred treatment option for
a patient presenting with metastatic non-clear cell disease (30).
Other therapeutic options include temsirolimus, sorafenib, suni-
tinib, pazopanib, axitinib, everolimus, bevacizumab, or erlotinib.
Of these treatments, only temsirolimus and bevacizumab have
been studied in a phase 3 clinical trial in which the effect of vari-
ous tumor histologies was independently analyzed. The following
section highlights the cellular pathways presumed to be altered
in non-clear cell tumors and the targeted agents that may yield a
clinical response.
NCCN RECOMMENDED AGENTS
mTOR PATHWAY
Mammalian target of rapamycin (mTOR) is a serine–threonine
kinase that serves as a central regulator of cell growth and prolifer-
ation, metabolism, and angiogenesis (31). mTOR is a downstream
component of the PI3K/AKT pathway, which is activated by the
tyrosine kinase cell surface receptors of insulin-like growth factor
(IGF), epidermal growth factor (EGF), platelet-derived growth
factor (PDGF), and vascular endothelial growth factor (VEGF).
The dysregulation of the PI3K/AKT/mTOR pathway is known to
be associated with many human cancers, including RCC.
Temsirolimus, an mTOR inhibitor, was approved for treat-
ment of advanced RCC after the ARCC trial. This large, multi-
institutional phase 3 trial studied the effects of temsirolimus as first
line therapy for poor-prognosis advanced RCC (32). A total of 626
patients were randomly assigned to temsirolimus, interferon-α,
or combination therapy. Patients randomized to the temsirolimus
group had a longer overall survival compared to the interferon
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and combination group (10.9 vs 7.3 and 8.4 months, respectively).
While this study included patients with all histologies of RCC, the
data suggested a more pronounced survival advantage in patients
with non-clear cell histology, which prompted a subgroup analysis
(Figure 2). In this analysis, they identified 73 patients with nccRCC
(37 randomized to temsirolimus arm and 36 to the interferon-α
arm) (33). Within this cohort, they observed an improved clinical
benefit (defined as complete or partial response or stable disease
≥24 weeks) of temsirolimus over interferon alpha (35.1 vs 8.3%,
respectively). They also observed a greater degree of improve-
ment among the non-clear cell subgroup compared to the clear
cell patients, but this finding was not statistically significant. The
authors speculated that the clinical improvement observed with
temsirolimus on non-clear cell tumors may be due to the criti-
cal role of angiogenesis in all RCC histologies as well as the close
relationship between mTOR and c-Met pathways. Temsirolimus is
the only agent with a NCCN category 1 recommendation (in poor
prognosis patients according to MSKCC criteria) for metastatic
non-clear cell disease (30). It has a category 2A recommendation
for all other prognostic risk groups.
Everolimus, another mTOR inhibitor, has been recently eval-
uated in two phase 2 trials in patients with metastatic nccRCC.
The RAPTOR trial (RAD001 in Advanced Papillary Tumor Pro-
gram in Europe) conducted by Escudier et al. enrolled patients
with metastatic papillary RCC and no prior therapy to receive
first line everolimus (34). Of the 92 patients studied, 59% of them
had stable disease after 6 months of therapy. Progression free sur-
vival was 7.8 months and at least half of the patients were alive at
20 months. Another trial by Koh et al. enrolled 43 patients with
metastatic non-clear cell disease to be treated with everolimus,
23 of whom had received prior VEGF therapy (35). Progression
free survival was 5.2 months and partial response was observed
in five patients (10%). Subgroup analysis revealed a substantially
longer progression free survival of 13.1 months in patients with
chromophobe tumors (n= 8).
VEGF PATHWAY
Angiogenesis is a crucial component of tumor growth and invasion
(36). This process is in part driven by migration and proliferation
of endothelial cells via activation of the VEGF receptor (a tyro-
sine kinase cell surface receptor). Dysregulated cancer cells secrete
abnormally high levels of angiogenic factors including VEGF in
order to recruit nearby vascular endothelial cells, which in turn
proliferate and form new blood vessels to deliver oxygen to the
highly metabolic tumors.
Two recent trials have compared sunitinib and everolimus
as first line therapy in metastatic nccRCC. The ESPN trial
FIGURE 2 | Hazard ratios (indicated by circles) with 95% confidence
intervals (indicated by horizontal lines) are shown for subgroups of
patients receiving interferon-α or temsirolimus.
randomized patients with non-clear cell disease to receive either
sunitinib or everolimus as first line therapy (37). Interim analy-
sis of 67 patients suggested an overall and progression free
survival advantage in the sunitinib arm (16.2 vs 14.9 and 6.1
vs 4.1 months, respectively). Additionally, a post hoc sub-group
analysis of metastatic nccRCC patients (n= 66) enrolled in the
RECORD-3 trial suggested a progression free survival advantage
of sunitinib (7.2 vs 5.1 months) (38).
There have been many single arm phase 2 trials studying the
role of VEGF inhibitors in patients with advanced nccRCC. Results
have been variable and overall treatment effect appears to be poor
to fair. A recent phase 2 trial studied the effect of sunitinib for
treatment of metastatic nccRCC (39). In this study, 23 patients
with various non-clear cell tumor histologies were enrolled (35%
of patients had papillary RCC). Progression free survival was
5.5 months for all patients (similar to the 5.6 months observed
in the papillary RCC subgroup). Overall response rate to suni-
tinib was poor, with only one patient achieving a partial response
(of note, the patient had unclassified histology). Another phase
2 trial treated 31 patients with non-clear cell tumors of various
histologies with sunitinib (40). Most patients (71%) had papil-
lary RCC. Overall response rate was 36% and median progression
free survival was 6.4 months. In the largest phase 2 trial to date
studying the role of sunitinib in advanced non-clear cell RCC,
Tannir et al. prospectively treated 57 patients with sunitinib 50 mg
daily on a 4-week-on, 2-week-off schedule (41). Patient eligi-
bility was expanded to both non-clear cell histology as well as
clear cell histology with >20% sarcomatoid features. The objec-
tive response rate was a dismal 5% and progression free survival
was 2.7 months; however, a subgroup analysis of the various tumor
histologies revealed more promising results in the chromophobe
RCC cohort, with a response rate of 40% and progression free sur-
vival of 12.7 months. The indolent nature of chromophobe tumors
and favorable prognosis associated with them has been previously
described (42).
Sunitinib has also demonstrated a moderate response in
patients with translocation associated RCC. In a retrospective
analysis of metastatic translocation associated RCC, the outcomes
of 21 patients were evaluated by systemic treatment given (43).
Patients treated with first line sunitinib (n= 11) had a significantly
longer progression free survival than those treated with cytokine
therapy (n= 9) (8.2 vs 2.0 months, respectively).
Another VEGF inhibitor, sorafenib, has been evaluated retro-
spectively for its utility in the setting of metastatic non-clear cell
RCC. A recent study by Choueiri et al. analyzed 53 patients with
papillary or chromophobe subtypes that were treated with either
sunitinib or sorafenib (44). The response rate and median pro-
gression free survival of all patients were 10% and 8.6 months,
respectively. Of note, patients with papillary tumors (n= 41)
demonstrated a longer progression free survival when treated
with sunitinib when compared to sorafenib (11.9 vs 5.1 months,
respectively).
Bevacizumab is a monoclonal antibody that selectively inhibits
the activity of human VEGF. The AVOREN trial (a phase 3 ran-
domized controlled trial of bevacizumab plus interferon vs inter-
feron alone) enrolled both patients with clear cell and mixed
histology RCC (45). This trial showed a clear advantage of the
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bevacizumab arm, showing significantly longer PFS (10.2 vs
5.4 months) and higher ORR (31 vs 13%). Out of the 649 enrolled
patients, 13% had some component of non-clear cell histology. A
secondary analysis of this subgroup revealed a survival advantage
of mixed histology patients with bevacizumab plus interferon vs
bevacizumab alone (5.7 vs 2.9 months, respectively) (46).
EGFR PATHWAY
The deregulated activation of EGFR is thought to play a signif-
icant role in RCC tumorigenesis. The rationale for treatment of
papillary RCC with EGFR inhibitors is based on data demonstrat-
ing cellular growth inhibition by blocking EGFR in the setting of
wildtype VHL expression (47). Papillary renal tumors are mole-
cularly defined by alterations in the c-Met oncogene (type 1) or
the fumarate hydratase gene (type 2) and do not typically have the
same VHL alterations as do their clear cell histology counterparts.
This prompted a phase 2 study conducted by Gordon et al.
in which erlotinib was given as first line treatment to 45 patients
with metastatic papillary RCC (48). Overall response rate was 11%,
disease control rate (partial response and stable disease) was 64%,
and median overall survival was 27 months. The investigators also
subdivided this group by EGFR staining intensity on immunohis-
tochemistry but there was no association with EGFR expression
and time to progression or overall survival.
OTHER INVESTIGATIONAL AGENTS
MET PATHWAY
The c-Met oncogene encodes the receptor tyrosine kinase for
hepatocyte growth factor (HGF). Once activated, this receptor
promotes pathways involved in cell growth, survival, and invasion
(49). An altered met oncogene (either due to activating mutations
or gene amplification) is the defining molecular feature of type 1
papillary RCC (8, 50).
This was the basis of a phase 2 trial conducted by Choueiri
et al. that investigated the effect of foretinib (a dual MET/VEGFR
inhibitor) in patients with metastatic papillary RCC (51). A total
of 74 patients were enrolled in this trial. The overall response rate
was 13% and median progression free survival was 9.3 months.
Interestingly, patients with a germline or somatic c-Met alteration
had a more drastic response to foretinib compared to those with
wildtype c-Met (50 vs 9%, respectively) (Figure 3).
Inhibitors of c-Met have been studied in translocation associ-
ated RCC as well (52). Tivantinib (ARQ197), a selective inhibitor
FIGURE 3 | Change in sum of longest tumor diameter. PR, partial
response.
of c-Met, was recently investigated in a multicenter single arm
phase 2 trial for treatment of microphthalmia transcription fac-
tor associated tumors (MiT’s). These tumors are characterized
by altered expression of certain E-box binding transcription fac-
tors, leading to dysregulated growth of certain cell lines (53). The
MiT family includes many tumors including translocation associ-
ated RCC, a malignancy of the kidney characterized by early age
of onset and a high metastatic potential (54). Of the 47 patients
enrolled in the tivantinib trial, 6 had translocation associated RCC.
There were no partial responses and 3/6 (50%) patients had stable
disease in the translocation associated RCC subgroup, and median
progression free survival was 1.9 months.
PROTEASOME PATHWAY
Proteolysis is a critical component of normal cell growth and pro-
liferation,and as such,when dysregulated can lead to unsuppressed
cell cycle activity and tumor production (55). Normal proteolysis
is carried out via the ubiquitin–proteasome system.
Recently bortezomib, an agent that inhibits the 26S proteasome,
was studied in a phase 2 trial for treatment of advanced RCC. The
trial included 37 patients with various tumor histologies (both
clear cell and non-clear cell). An objective response rate of 11% was
observed, but it is worth noting that the one patient with medullary
RCC had an extraordinary response to therapy, showing a com-
plete response after 7 months of treatment and remained without
evidence of disease at 27 months (56). The investigators recom-
mended further investigation of the role of ubiquitin–proteasome
inhibitors in advanced medullary RCC.
CHEMOTHERAPY OPTIONS
The role of multi-agent chemotherapy for treatment of collect-
ing duct RCC is actively being investigated due to its close bio-
logic resemblance to upper tract urothelial carcinoma. Recently,
a phase 2 trial of gemcitabine plus platinum salt for metastatic
collecting duct carcinoma was conducted (57). The study eval-
uated the responses of 23 patients treated with this multi-agent
chemotherapy regimen as first line therapy. Patients had an objec-
tive response rate of 26%, median progression free survival of
7.1 months, and median overall survival of 10.5 months. There
are multiple case reports documenting the response of metastatic
collecting duct and medullary RCC to multi-agent chemother-
apy. Gollob et al. described a woman with advanced collecting
duct carcinoma who had an 80% response to taxol/carboplatin
therapy (58). Another patient with metastatic collecting duct
carcinoma reported by Milowsky et al. had a 68% response to dox-
orubicin and gemcitabine (59). Lastly, three young patients with
metastatic medullary RCC achieved a partial response to high dose
methotrexate, vinblastine, doxorubicin, and cisplatin as reported
by Rathmell et al. (60).
ROLE OF SURGERY
There is a well-established clinical benefit of cytoreductive
nephrectomy in the setting of metastatic RCC (61, 62). Although
two landmark randomized trials studying the effect of cytoreduc-
tive nephrectomy were conducted prior to the widespread accepted
use of targeted therapy, there still appears to be a survival benefit
in patients with metastatic disease who are able to tolerate surgery.
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There are currently two ongoing trials addressing the clinical util-
ity of cytoreductive nephrectomy in the era of targeted therapy: (1)
the CARMENA study, which randomized patients into nephrec-
tomy plus sunitinib vs sunitinib alone, and (2) the SURTIME
study, which randomized patients into neoadjuvant sunitinib plus
nephrectomy vs nephrectomy plus adjuvant sunitinib (63).
Kassouf et al. recently reviewed the M.D. Anderson Cancer
Center experience of cytoreductive nephrectomies in non-clear
cell disease (64). Of the 606 nephrectomies performed in patients
with metastatic RCC, 92 had nccRCC. Patients with nccRCC
were younger and had a higher incidence of nodal metastases.
The disease specific survival was also worse in nccRCC patients
undergoing cytoreductive nephrectomy when compared to ccRCC
patients (9.7 vs 20.3 months). In contrast to these results, a review
of the Mayo Clinic experience with cytoreductive nephrectomies
(n= 505) reported by Carrasco et al. did not reveal an association
of adverse survival in patients with non-clear cell disease (65).
Overall, the utilization of cytoreductive nephrectomy still plays
an important role in metastatic RCC, regardless of histologic sub-
type. Aizer et al. recently investigated the role of cytoreductive
nephrectomy in nccRCC through outcomes analysis of the SEER
database (66). They found an overall RCC-specific and overall sur-
vival advantage among patients with nccRCC, who had undergone
cytoreductive nephrectomy. When histologic subtypes were inde-
pendently assessed, those with chromophobe and collecting duct
pathology derived similar survival advantage to conventional clear
cell tumors. While patients with papillary tumors had a decreased
RCC-specific mortality after undergoing cytoreductive nephrec-
tomy, the magnitude of this advantage was less than patients with
ccRCC (HR 0.71 vs 0.48, respectively).
FUTURE STUDIES
Phase 3 trials for nccRCC are very difficult to conduct due to
low disease prevalence. As such, clinical trials typically enroll both
ccRCC and nccRCC patients, with stratification of both disease
groups in each treatment arm. The following ongoing phase 3
trials are incorporating this strategy: NCT00326898 (adjuvant
sunitinib vs adjuvant sorafenib after nephrectomy), NCT00492258
(adjuvant sorafenib vs placebo after nephrectomy), NCT01120249
(adjuvant everolimus vs placebo after nephrectomy) (63).
There are also a number of phase 2 studies focusing on nccRCC
currently ongoing and/or recruiting participants. The therapeu-
tic agents being investigated (either alone or in combination)
include sunitinib (NCT01108445, NCT01185366, NCT00465179,
NCT00979966, NCT01034878, NCT01219751, NCT01673386,
NCT00326898, NCT01164228), sorafenib (NCT00326898), tem-
sirolimus (NCT00979966), everolimus (NCT01108445, NCT0
1185366, NCT00830895, NCT01399918, NCT00688753, NCT012
39342), Akt inhibitor MK2206 (NCT01239342), bevacizumab
(NCT01399918), pazopanib (NCT01538238, NCT01767636), axi-
tinib (NCT01798446), bortezomib (NCT00276614), tivozanib
(NCT01297244,NCT01673386), crizotinib (NCT01524926), fore-
tinib (NCT00726323), gemcitabine (NCT00491075, NCT004
01128, NCT01164228), capecitabine (NCT01182142, NCT002267
98), pemetrexed (NCT00491075), irinotecan (NCT00401128),
fludarabine (NCT00027820, NCT00078858, NCT00243009),
epothilone b (NCT00035243).
CONCLUSION
There have been significant strides made in the treatment of
metastatic RCC in the last decade, including the development of
targeted therapies and the increased utilization of cytoreductive
nephrectomy. While most prospective trials have included patients
with all histologies of RCC, it is important to remember that the
less common subtypes can display very different clinical behavior
and response to therapy. Currently, there is no widely accepted first
line therapy for metastatic nccRCC, and as such, enrollment in a
clinical trial is the preferred option according to NCCN guidelines.
Other considerations should be temsirolimus, sorafenib, sunitinib,
pazopanib, axitinib, everolimus, bevacizumab, or erlotinib. Due to
the low prevalence of this disease spectrum, it is of critical impor-
tance for there to be multi institutional collaboration in efforts to
conduct prospective clinical trials of novel treatments for patients
with metastatic nccRCC.
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